Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas

British Journal of Cancer

Volumn 107, Issue 2, 2012, Pages 300-307

  Rahman, M T ^a   Nakayama, K ^a   Rahman, M ^a   Katagiri, H ^a   Katagiri, A ^a   Ishibashi, T ^a   Ishikawa, M ^a   Iida, K ^a   Nakayama, N ^a   Otsuki, Y ^b   Nakayama, S ^b   Miyazaki, K ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

Author keywords

C75; fatty acid synthase; NAC1; ovarian clear cell carcinoma; survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; IRINOTECAN; NAC1 PROTEIN; NACC1 PROTEIN; ONCOPROTEIN; PACLITAXEL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; CYTOREDUCTIVE SURGERY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84863727675     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.246     Document Type: Article

References (44)

1. Abhiman S, Iyer LM, Aravind L (2008) BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinformatics 24: 458-461
2. Alo PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE, Di Tondo U (2000) Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7: 1383-1388
3. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482
4. Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313
5. Coleman DT, Bigelow R, Cardelli JA (2009) Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 8: 214-224
6. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP (2007) Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 6: 1263-1268
7. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M (2008) Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 88: 1340-1348
8. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, Liu W, Ericsson J, Watabe K (2008) Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 68: 1003-1011
9. Gansler TS, Hardman 3rd W, Hunt DA, Schaffel S, Hennigar RA (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28: 686-692
10. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller Jr AF (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412-417
11. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
12. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K (2008) A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 14: 3149-3155
13. Jackowski S, Wang J, Baburina I (2000) Activity of the phosphatidylcholine biosynthetic pathway modulates the distribution of fatty acids into glycerolipids in proliferating cells. Biochim Biophys Acta 1483: 301-315
14. Jinawath N, Vasoontara C, Yap KL, Thiaville MM, Nakayama K, Wang TL, Shih IM (2009) NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 28: 1941-1948
15. Korutla L, Degnan R, Wang P, Mackler SA (2007) NAC1, a cocaineregulated POZ/BTB protein interacts with CoREST. J Neurochem 101: 611-618
16. Korutla L, Wang P, Jackson TG, Mackler SA (2009) NAC1, a POZ/BTB protein that functions as a corepressor. Neurochem Int 54: 245-252
17. Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66: 5977-5980
18. Little JL, Wheeler FB, Koumenis C, Kridel SJ (2008) Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 7: 3816-3824
19. Ma T, Wang Z, Guo Y, Pei D (2009) The C-terminal pentapeptide of Nanog tryptophan repeat domain interacts with Nac1 and regulates stem cell proliferation but not pluripotency. J Biol Chem 284: 16071-16081
20. Menendez JA, Vellon L, Lupu R (2005) Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 64: 997-1001
21. Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y (2001) Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8: 1285-1287
22. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih Ie M (2006) A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 103: 18739-18744
23. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M, Wang TL (2007) Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120: 2613-2617
24. Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K (2010) Biological role and prognostic significance of NAC1 in ovarian cancer. Gynecol Oncol 119: 469-478
25. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB (2001) Increased fatty acid synthase as a therapeutic target in androgenindependent prostate cancer progression. Prostate 47: 102-110
26. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, Kuhajda FP, Hamilton SR (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150: 201-208
27. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715
28. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
29. Shih Ie M, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL (2011) Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol 24: 638-645
30. Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG (2005) Sequence and structural analysis of BTB domain proteins. Genome Biol 6: R82
31. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589
32. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih Ie M (2010) Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010: 285191
33. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62: 642-646
34. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA (2008) Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 41: 59-85
35. Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28: 4523-4530
36. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH (2006) A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368
37. Wingo PA, Tong T, Bolden S (1995) Cancer statistics, 1995. CA Cancer J Clin 45: 8-30
38. Winter 3rd WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627
39. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752
40. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogenactivated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90
41. Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW, Pizer ES (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282: 132-137
42. Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N, Miyazaki K (2008) Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 14: 1686-1691
43. Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, Patel R, Liu D, Qin ZH, Shih IM, Yang JM (2012) NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 31: 1055-1064
44. Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, El Meskini R, Ronnett GV, Townsend CA, Kuhajda FP (2007) Fatty acid synthase inhibition activates AMPactivated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67: 2964-2971